Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
Consumers can purchase four weekly treatments at once or choose a subscription at a discounted price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dermata Therapeutics (DRMA) announced topline results from a completed cosmetic study evaluating its recently launched Tome Foundational Treatment.
The open-label study, in which treatment was known, included 31 participants who applied the treatment once weekly for four weeks. Investigator assessments covered skin appearance, and participants completed self-evaluations after four treatments. 93% agreed the treatment was comparable to a professional in-office procedure, while 90% agreed they saw more noticeable results compared with other products. No treatment-related adverse events were reported. Tome is Dermata's first commercial product and is available for purchase.
Positive
- Minor pointTome Foundational Treatment, Dermata's first commercial product, is now available for purchase.
- Minor point93% of participants agreed Tome Foundational Treatment was comparable to a professional in-office procedure.
- Minor point90% of participants agreed they saw more noticeable results compared with other products.
- Minor pointNo treatment-related adverse events were reported in the completed cosmetic study.
Negative
- Minor pointStudy evidence is limited to 31 participants using treatment for four weeks in an open-label design.
Details
Market move: DRMA +40.04% vs previous close. Tome cosmetic clinical data
On Oct 15, the day this news came out, the latest delayed price for DRMA is 40.04% above the previous close. Argus tracked a peak move of +41.7% during the session. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner has recorded 49 alerts for this stock so far that day. The latest delayed price is $0.93. Relative volume is exceptionally heavy at 491.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Study participants
- 31 participants
- Open-label cosmetic clinical study
- Treatment regimen
- 4 weekly treatments
- Cosmetic clinical study
- Participant agreement
- 93%
- Agreed treatment was comparable to a professional in-office procedure
- Participant-reported results
- 90%
- Agreed they saw more noticeable results compared with other products
- Treatment-related adverse events
- None reported
- Cosmetic clinical study
Key Terms
open label technical
hyperpigmentation medical
adverse events medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / October 15, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment. Tome Foundational Treatment is now available for purchase at www.tomeskincare.com either as a one-time purchase of four weekly treatments or through a subscription program at a discounted price.
Dermata's recently completed cosmetic clinical study consisted of 31 participants in an open label study of Tome Foundational Treatment. Participants applied Tome Foundational Treatment one time per week for four weeks and were evaluated by an investigator at multiple timepoints throughout the study on endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance, and overall appearance. Participants also completed self-evaluations after four treatments.
The topline clinical study findings include:
Additionally,
"We are extremely encouraged by these topline results, which provide clinical support for what we set out to accomplish with Tome, to create a fundamentally different approach to skincare," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "Dermata was founded on clinical rigor, and we believe these data help provide the backing for our claim that Tome is ‘studied skincare'. We believe these topline results demonstrate the potential that a once-weekly skin treatment can visibly renew the appearance of the skin and provide compelling clinical validation at an important time as we introduce Tome to consumers," continued Mr. Proehl. "We are encouraged by the reception we have seen from the recent launch of Tome Foundational Treatment and look forward to expanding its recognition in the skincare space. We continue to build awareness around the Tome brand, and believe these clinically demonstrated results, combined with the simplicity of a once-weekly routine, can provide meaningful differentiation for Tome Foundational Treatment in the premium skincare market," concluded Mr. Proehl.
Tome Foundational Treatment: A New Foundation for Your Skincare Routine
Tome Foundational Treatment is a once-weekly skin renewal treatment powered by Bioneedle™, Dermata's hero ingredient consisting of
About Tome Skincare
Tome is Dermata's skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome consists of skincare products utilizing Spongilla lacustris, a wild harvested freshwater sponge that has evolved over centuries, for consumers compelled by history and science to find potent natural products for their skincare routine. Dermata believes its Tome skincare line can simplify existing skincare routines with essential ingredients designed to deliver results, without harmful extremes.
Start your skincare story at Tome.
About Dermata Therapeutics
Dermata Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer and professional skincare solutions. The Company leverages its experience in clinical dermatology and its Bioneedle technology to develop differentiated skincare products designed to address a variety of consumer skincare needs. Dermata's first commercial product, Tome Foundational Treatment, is now available at Tome, with additional innovations planned to follow. Dermata is headquartered in San Diego, California.
For more information, please visit Dermata.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to commercialize skincare products; the timing of any future announcements; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, market acceptance of its products, and expansion into broader consumer markets; the expected timing and success of any planned product launches; the potential market acceptance of any products; the proposed benefits any clinical data will provide support for any products commercial success; the Company's plan to incorporate study results into any marketing activities; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Dermata Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dermata's Tome Foundational Treatment cosmetic study show?
93% of participants agreed the treatment was comparable to a professional in-office procedure, and 90% agreed they saw more noticeable results compared with other products. These were participant-reported findings. No treatment-related adverse events were reported during the study.